Secreted acid sphingomyelinase as a potential gene therapy for limb girdle muscular dystrophy 2B.
Ontology highlight
ABSTRACT: Efficient sarcolemmal repair is required for muscle cell survival, with deficits in this process leading to muscle degeneration. Lack of the sarcolemmal protein dysferlin impairs sarcolemmal repair by reducing secretion of the enzyme acid sphingomyelinase (ASM), and causes limb girdle muscular dystrophy 2B (LGMD2B). The large size of the dysferlin gene poses a challenge for LGMD2B gene therapy efforts aimed at restoring dysferlin expression in skeletal muscle fibers. Here, we present an alternative gene therapy approach targeting reduced ASM secretion, the consequence of dysferlin deficit. We showed that the bulk endocytic ability is compromised in LGMD2B patient cells, which was addressed by extracellularly treating cells with ASM. Expression of secreted human ASM (hASM) using a liver-spe
SUBMITTER: Bittel DC
PROVIDER: S-EPMC8718136 | biostudies-literature | 2022 Jan
REPOSITORIES: biostudies-literature
ACCESS DATA